Biotech With Billion-Dollar Potential? ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | A message from Interactive Offers As U.S. measles vaccination rates continue to fall, Stanford scientists now warn the virus could become endemic within just a few years. In a world still reeling from the COVID-19 pandemic, a resurgence of viral threats is raising urgent alarm—and opportunity. But one small-cap biotech company is preparing to lead a counterattack. NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage company developing revolutionary broad-spectrum antiviral drugs that could potentially target a wide range of high-risk viruses, including measles, RSV, influenza, long COVID, and more. - NV-387 has demonstrated potential to combat 90–95% of known human pathogenic viruses
- The company has begun testing against measles in preclinical models
- There are currently no approved treatments for RSV or measles
- NV-387's animal model results for RSV showed complete viral clearance
- Float under 16M and a market cap under $30M could fuel big moves if demand spikes The market has already taken notice:
📈 Recently broke past all major technical moving averages
📈 Recently hit a 6-month high  Why the Broader Market Opportunity Is Even Bigger: The global biotech market was valued at $1.55 trillion in 2023 and is projected to reach $3.88 trillion by 2030. With health systems under pressure and virus threats on the rise, antiviral innovation is now a priority sector for public and private investment worldwide. NanoViricides may be positioned to ride that wave. This could be a rare opportunity to catch a tiny biotech firm just as it steps onto a bigger stage—with real science, real trials, and real momentum.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $7000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between June 26, 2025 and July 2, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
Today's Bonus Content: 7 Stocks to Buy and Hold Forever
(By clicking the link, you will get this free report and a free subscription to MarketBeat's daily email newsletter. Unsubscribe at any time.) | | |
|
